Risk factors for non-adherence to oral anticoagulant therapy and the potential of their modification in patients with atrial fibrillation: a narrative literature review
https://doi.org/10.15829/1560-4071-2024-6140
EDN: WVECZM
Abstract
Medication adherence is a key factor of effective stroke prevention in patients with atrial fibrillation receiving oral anticoagulant therapy. At the same time, patient compliance can significantly decrease over time, which leads to an increased thromboembolism risk. A number of studies have shown that a large number of patients receiving anticoagulant therapy are insufficiently adherent to therapy (according to various sources, from 30 to 50% of patients do not comply with the prescribed treatment regimen or interrupt therapy).
Independent risk factors for non-compliance include younger age, old age, prior stroke, male sex, multimorbidity, polypharmacy. The risk of decreased compliance with double drug intake compared to single one is noted separately.
The review aim is to study the risk factors for non-adherence to oral anticoagulants in patients with atrial fibrillation and possible measures for its prevention.
Supporting agencies: The publication was prepared with the support of Bayer.
About the Authors
I. M. Felikov
AO Bayer
Russian Federation
Competing Interests:
Russian Federation
Ignat M. Felikov.
Moscow
Competing Interests:
None
V. V. Kashtalap
Research Institute for Complex Issues of Cardiovascular Diseases
Russian Federation
Competing Interests:
Russian Federation
Vasiliy V. Kashtalap.
Kemerovo
Competing Interests:
None
References
1. Ozaki AF, Choi AS, Le QT, et al. Real-world adherence and persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis. Circulation: Cardiovascular Quality and Outcomes. 2020;13(3):e005969. doi:10.1161/CIRCOUTCOMES.119.005969.
2. Salmasi S, Loewen PS, Tandun R, et al. Adherence to oral anticoagulants among patients with atrial fibrillation: a systematic review and meta-analysis of observational studies. BMJ open. 2020;10(4):e034778. doi:10.1136/bmjopen-2019-034778.
3. Desteghe L, Vijgen J, Koopman P, et al. Telemonitoring-based feedback improves adherence to non-vitamin K antagonist oral anticoagulants intake in patients with atrial fibrillation. European heart journal. 2018;39(16):1394-403. doi:10.1093/eurheartj/ehx762.
4. Márquez-Contreras E, Martell-Claros N, Márquez-Rivero S, et al. Strategies for improving dabigatran adherence for stroke prevention in patients with non-valvular atrial fibrillation: education and drug intake reminders (FACILITA study). Current medical research and opinion. 2018;34(7):1301-8. doi:10.1080/03007995.2018.1435519.
5. Nikolaev NA, Martynov AI, Skirdenko YuP, et al. Management of treatment on the basis of adherence. Consilium Medicum. 2020;22(5):9-18. (In Russ.) doi:10.26442/20751753.2020.5.200078.
6. De Geest S, Sabaté E. 2003 Adherence to long-term therapies: evidence for action. European Journal of Cardiovascular Nursing. 2003;2(4):323. doi:10.1016/S1474-5151(03)00091-4.
7. Drapkina OM, Livzan MA, Martynov AI, et al. The first Russian expert consensus on the quantitative evaluation of the treatment adherence: pivotal issues, algorithms and recommendations. Medical News of the North Caucasus. 2018;13(1-2):259-71. (In Russ.) doi:10.14300/mnnc.2018.13039.
8. Maffoni M, Traversoni S, Costa E, et al. Medication adherence in the older adults with chronic multimorbidity: a systematic review of qualitative studies on patient's experience. European geriatric medicine. 2020;11:369-81. doi:10.1007/s41999-020-00313-2.
9. Visseren FL, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). European heart journal. 2021;42(34):3227-37. doi:10.1093/eurjpc/zwab154.
10. Chaudri NA. Adherence to Long-term Therapies Evidence for Action. Ann Saudi Med. 2004;24(3):221-2. doi:10.5144/0256-4947.2004.221.
11. Beyer-Westendorf J, Ehlken B, Evers T. Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation. Europace. 2016;18(8):1150-7. doi:10.1093/europace/euv421.
12. Deshpande CG, Kogut, S, Willey C. Real-world health care costs based on medication adherence and risk of stroke and bleeding in patients treated with novel anticoagulant therapy. Journal of managed care & specialty pharmacy. 2018;24(5):430-9. doi:10.18553/jmcp.2018.24.5.430.
13. Jackevicius CA, Tsadok MA, Essebag V, et al. Early non-persistence with dabigatran and rivaroxaban in patients with atrial fibrillation. Heart. 2017;103(17):1331-8. doi:10.1136/heartjnl-2016-310672.
14. World Health Organization. Adherence to long-term therapies: evidence for action. Geneva: WHO Library Cataloguing-in-Publication Data, 2003:5-169. ISBN: 9241545992.
15. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119(23):3028-35. doi:10.1161/CIRCULATIONAHA.108.768986.
16. Komen JJ, Pottegard A, Mantel-Teeuwisse AK, et al. Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries. Europace. 2021;23(11):1722-30. doi:10.1093/europace/euab091.
17. Lukina YuV, Kutishenko NP, Martsevich SYu, et al. Questionnaires and scores for assessing medication adherence — advantages and disadvantages of the diagnostic method in research and actual clinical practice. Cardiovascular Therapy and Prevention. 2020;19(3):2562. (In Russ.) doi:10.15829/1728-8800-2020-2562.
18. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67-74. doi:10.1097/00005650-198601000-00007.
19. Moon SJ, Lee WY, Hwang JS, et al. Accuracy of a screening tool for medication adherence: A systematic review and meta-analysis of the Morisky Medication Adherence Scale-8. PLoS One. 2017;12(11):e0187139. doi:10.1371/journal.pone.0187139.
20. Sakthong P, Chabunthom R, Charoenvisuthiwongs R. Psychometric properties of the Thai version of the 8-item Morisky Medication Adherence Scale in patients with type 2 diabetes. Ann Pharmacother. 2009;43(5):950-7. doi:10.1345/aph.1L453.
21. Svarstad BL, Chewning BA, Sleath BL, et al. The Brief Medication Questionnaire: a tool for screening patient adherence and barriers to adherence. Patient Educ Couns. 1999;37(2):113-24. doi:10.1016/s0738-3991(98)00107-4.
22. Kripalani S, Risser J, Gatti ME, et al. Development and evaluation of the Adherence to Refills and Medications Scale (ARMS) among low-literacy patients with chronic disease. Value Health. 2009;12(1):118-23. doi:10.1111/j.1524-4733.2008.00400.x.
23. Nikolayev NA, Skirdenko YuP. Russian generic questionnaire for evaluation of compliance to drug therapy. Clin. Pharmacol. Ther. 2018;27(1):74-8. (In Russ.)
24. Lukina YuV, Kutishenko NP, Tolpygina SN, et al. Main factors of adherence to new oral anticoagulants and its dynamics in outpatients with nonvalvular atrial fibrillation: results of the ANTEY study. Cardiovascular Therapy and Prevention. 2020;19(5):2680. (In Russ.) doi:10.15829/1728-8800-2020-2680.
25. van der Horst SF, de Vries TA, Chu G, et al. Prevalence and predictors of nonadherence to direct oral anticoagulant treatment in patients with atrial fibrillation. TH Open. 2023;7(03):e270-e279. doi:10.1055/a-2161-0928.
26. Perreault S, de Denus S, White-Guay B, et al. Oral Anticoagulant Prescription Trends, Profile Use, and Determinants of Adherence in Patients with Atrial Fibrillation. Pharmacotherapy. 2020;40(1):40-54. doi:10.1002/phar.2350.
27. Zielinski GD, van Rein N, Teichert M, et al. Adherence to direct oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study. Pharmacoepidemiol Drug Saf. 2021;30(8):1027-36. doi:10.1002/pds.5242.
28. Brown JD, Shewale AR, Talbert JC. Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention for Newly Diagnosed and Treatment-Naive Atrial Fibrillation Patients: An Update Using 2013-2014 Data. J Manag Care Spec Pharm. 2017;23(9):958-67. doi:10.18553/jmcp.2017.23.9.958.
29. Banerjee A, Benedetto V, Gichuru P, et al. Adherence and persistence to direct oral anticoagulants in atrial fibrillation: a population-based study. Heart. 2020;106(2):119-26. doi:10.1136/heartjnl-2019-315307.
30. Lapa ME, Swabe GM, Magnani JW. Association of Depression and Adherence to Oral Anticoagulation in Patients With Atrial Fibrillation. Journal of the American Heart Association. 2023;12(22):e031281. doi:10.1161/JAHA.123.031281.
31. McHorney CA, Ashton V, Laliberté F, et al. Adherence to Rivaroxaban Compared with Other Oral Anticoagulant Agents Among Patients with Nonvalvular Atrial Fibrillation. J Manag Care Spec Pharm. 2017;23(9):980-8. doi:10.18553/jmcp.2017.23.9.980.
32. Jacobs MS, Schouten JF, de Boer PT, et al. Secondary adherence to non-vitamin-K antagonist oral anticoagulants in patients with atrial fibrillation in Sweden and the Netherlands. Curr Med Res Opin. 2018;34(10):1839-47. doi:10.1080/03007995.2018.1459528.
33. Coleman CI, Roberts MS, Sobieraj DM, et al. Effect of dosing frequency on chronic cardiovascular disease medication adherence. Curr Med Res Opin. 2012;28(5):669-80. doi:10.1185/03007995.2012.677419.
34. Srivastava K, Arora A, Kataria A, et al. Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis. Patient Prefer Adherence. 2013;7:419-34. doi:10.2147/PPA.S44646.
35. Weeda ER, Coleman CI, McHorney CA, et al. Impact of once- or twice-daily dosing frequency on adherence to chronic cardiovascular disease medications: A metaregression analysis. Int J Cardiol. 2016;216:104-9. doi:10.1016/j.ijcard.2016.04.082.
36. Pham PN, Brown JD. Real-world adherence for direct oral anticoagulants in a newly diagnosed atrial fibrillation cohort: does the dosing interval matter? BMC Cardiovascular Disorders. 2019;19:1-10. doi:10.1186/s12872-019-1033-3.
37. Godinas L, Dobbels F, Hulst L, et al. Once daily tacrolimus conversion in lung transplantation: A prospective study on safety and medication adherence. J Heart Lung Transplant. 2021;40(6):467-77. doi:10.1016/j.healun.2021.02.017.
38. de Llano LP, Sanmartin AP, González-Barcala FJ, et al. Assessing adherence to inhaled medication in asthma: Impact of once-daily versus twice-daily dosing frequency. The ATAUD study. J Asthma. 2018;55(9):933-8. doi:10.1080/02770903.2018.1426769.
39. Elnaem MH, Irwan NA, Abubakar U, et al. Impact of Medication Regimen Simplification on Medication Adherence and Clinical Outcomes in Patients with Long-Term Medical Conditions. Patient Prefer Adherence. 2020;14:2135-45. doi:10.2147/PPA.S268499.
40. Syed YY. Perindopril/Indapamide/Amlodipine in Hypertension: A Profile of Its Use. Am J Cardiovasc Drugs. 2022;22(2):219-30. doi:10.1007/s40256-022-00521-0.
41. McHorney CA, Peterson E, Ashton V, et al. Adherence to QD vs. BID Medications in NVAF Patients is Associated With Reduced Risk of Ischemic Stroke: A Modeling Study Using RCT and Claims Data. Circulation. 2016;134(suppl_1):A15087-A15087. doi:10.1161/circ.134.suppl_1.15087.
42. Turov AN, Panfilov SV, Tschiglinzeva ОV. The Efficacy, Safety and Adherence to Treatment when New Anticoagulants Taking in Over 75 Years Old Patients with Atrial Fibrillation. Rational Pharmacotherapy in Cardiology. 2020;16(1):10-8. (In Russ.) doi:10.20996/1819-6446-2020-20-07.
Supplementary files
Review
For citations:
Felikov I.M., Kashtalap V.V. Risk factors for non-adherence to oral anticoagulant therapy and the potential of their modification in patients with atrial fibrillation: a narrative literature review. Russian Journal of Cardiology. 2024;29(10):6140. (In Russ.) https://doi.org/10.15829/1560-4071-2024-6140. EDN: WVECZM
Views:
628
Email this article 